Carisma Therapeutics, Inc. (CARM) Earnings History
Profitable14 years of earnings data (2011–2024) · Positive TTM net income
Loading earnings history...
Carisma Therapeutics, Inc. (CARM) Earnings Overview
As of July 8, 2026, Carisma Therapeutics, Inc. (CARM) reported trailing twelve-month net income of $8M, reflecting +43.6% year-over-year growth. The company earned $0.19 per diluted share over the past four quarters, with a net profit margin of -308.1%.
Looking at the long-term picture, CARM's historical earnings data spans multiple years. The company achieved its highest annual net income of $2M in fiscal 2016.
Carisma Therapeutics, Inc. maintains positive profitability with a gross margin of -204.0%, operating margin of -316.7%, and net margin of -308.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including MGTX (-$121M net income, -140.3% margin), FATE (-$130M net income, -2051.1% margin), SANA (-$242M net income), CARM has room to improve margins relative to the peer group. Compare CARM vs MGTX →
CARM Earnings vs Peers
Earnings metrics vs comparable public companies
CARM Historical Earnings Data (2011–2024)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$60M | +30.4% | -$62M | $-1.46 | -308.1% | -316.7% |
| 2023 | -$87M | -41.9% | -$89M | $-2.59 | -582.3% | -594.8% |
| 2022 | -$61M | -18122.0% | -$56M | $-1.52 | -622.6% | -571.1% |
| 2021 | $-336,000 | +98.8% | -$28M | $-0.04 | -1.3% | -106.1% |
| 2020 | -$28M | +73.6% | -$28M | $-3.81 | -252.3% | -252.6% |
| 2019 | -$108M | -219.1% | -$37M | $-23.64 | - | - |
| 2018 | -$34M | -16.1% | -$26M | $-10.91 | - | - |
| 2017 | -$29M | -1635.1% | -$20M | $-22.24 | -6830.4% | -4702.4% |
| 2016 | $2M | +105.7% | $6M | $1.74 | 6.3% | 20.6% |
| 2015 | -$33M | +3.1% | -$35M | $-35.23 | -3379.0% | -3555.2% |
| 2014 | -$35M | -77.8% | -$33M | $-47.16 | -1539.5% | -1468.2% |
| 2013 | -$19M | +2.0% | -$17M | $-45.50 | -1456.1% | -1246.3% |
| 2012 | -$20M | -52.8% | -$19M | $-55.70 | - | - |
| 2011 | -$13M | - | -$13M | $-30.39 | - | - |
Download Data
Export CARM earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CARM — Frequently Asked Questions
Quick answers to the most common questions about buying CARM stock.
What is CARM earnings per share (EPS)?
CARM trailing twelve-month (TTM) diluted EPS is $0.19, reflecting +43.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2024 is available in the table on this page.
What is Carisma Therapeutics, Inc.'s net income?
Carisma Therapeutics, Inc. (CARM) trailing twelve-month net income is $8M as of 2024. Earnings grew +43.6% year-over-year.
Is CARM profitable?
Yes, CARM is profitable with a TTM net income of $8M and a net profit margin of -308.1%.
What is CARM's earnings growth rate?
CARM compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2024.
What are CARM's profit margins?
Carisma Therapeutics, Inc. net profit margin is -308.1%, operating margin is -316.7%, and gross margin is -204.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is CARM growing earnings?
Yes, CARM earnings are accelerating — EPS growth of +43.6% exceeds the 5-year CAGR of N/A. TTM net income reached $8M. Earnings momentum is strengthening.
What was CARM's best earnings year?
Carisma Therapeutics, Inc.'s highest annual net income on record is $2M, achieved in fiscal year 2016. Earnings history on this page spans 2011 to 2024 and includes all annual and quarterly figures.
What were CARM's earnings last quarter?
CARM's most recent reported quarter was Q3 2025. Net income was $45M with diluted EPS of $1.07. For a full breakdown of all quarters, see the quarterly earnings table on this page.